A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn’s disease

Naismith, G. D., Smith, L. A., Barry, S. J.E. , Munro, J. I., Laird, S., Rankin, K., Morris, A. J., Winter, J. W. and Gaya, D. R. (2014) A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn’s disease. Journal of Crohn's and Colitis, 8(9), pp. 1022-1029. (doi: 10.1016/j.crohns.2014.01.029)

[img]
Preview
Text
90530.pdf - Accepted Version

241kB

Abstract

Background: The faecal calprotectin (FC) test is a non-invasive marker for gastrointestinal inflammation. Aim: To determine whether higher FC levels in individuals with quiescent Crohn’s disease are associated with clinical relapse over the ensuing 12 months.<p></p> Methods: A single centre prospective study was undertaken in Crohn's disease patients in clinical remission attending for routine review. The receiver operating characteristic (ROC) curve for the primary endpoint of clinical relapse by 12 months, based on FC at baseline, was calculated. Kaplan-Meier curves of time to relapse were based on the resulting optimal FC cutoff for predicting relapse.<p></p> Results: Of 97 patients recruited, 92 were either followed up for 12 months without relapsing, or reached the primary endpoint within that period. Of these, 10 (11%) had relapsed by 12 months. The median FC was lower for non-relapsers, 96µg/g (IQR 39-237), than for relapsers, 414µg/g (IQR 259-590), (p=0.005). The area under the ROC curve to predict relapse using FC was 77.4%. An optimal cutoff FC value of 240µg/g to predict relapse of quiescent Crohn’s had sensitivity of 80.0% and specificity of 74.4%. Negative predictive value was 96.8% and positive predictive value was 27.6%. FC≥240μg/g was associated with likelihood of relapse 5.7 (95% CI 1.9-17.3) times higher within 2.3 years than lower values (p=0.002).<p></p> Conclusions: In this prospective dataset, FC appears to be a useful, non-invasive tool to help identify quiescent Crohn’s disease patients at a low risk of relapse over the ensuing 12 months. FC of 240µg/g was the optimal cutoff in this cohort.<p></p>

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Winter, Dr Jack and Gaya, Mr Daniel and Barry, Dr Sarah
Authors: Naismith, G. D., Smith, L. A., Barry, S. J.E., Munro, J. I., Laird, S., Rankin, K., Morris, A. J., Winter, J. W., and Gaya, D. R.
College/School:College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Robertson Centre
Journal Name:Journal of Crohn's and Colitis
Publisher:Elsevier
ISSN:1873-9946
ISSN (Online):1876-4479
Copyright Holders:Copyright © 2014 Elsevier
First Published:First published in Journal of Crohn’s and Colitis 8(9):1022-1029
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher.

University Staff: Request a correction | Enlighten Editors: Update this record